Abstract:Abstract Background: Low-risk patients with acute promyelocytic leukemia (APL) can be cured using only ATRA and arsenic trioxide (ATO), without chemotherapy(Lo-Coco F, et al. NEJM 2013) .Our group simplified the protocol by replacing iv ATO with oral arsenic, referred to as RIF, allowing for outpatient, oral and chemotherapy-free treatment for an increasing number of APL patients (Zhu HH, et al. NEJM 2014; 371:2239-41;Zhu HH, et al. Lancet Oncol 2018;19:871-879; Zhu HH, et al. Blood 2019;134:597-605). We also reported a promising single-center results using chemo-free postremission treatment for high-risk APL patients (Zhu HH, Blood 2018;131:2987-2989), which need to be confirmed in a well designed multi-center trial. Objective: To evaluate the efficacy of safety Realgar indigo formula plus retinoic acid as postremission treatment in an oral and chemo-free model for high-risk APL patients . Design, setting and participants: a prospective, multicenter, single-arm, phase II clinical trial conducted in the First Affiliated Hospital, Zhejiang University College of Medicine, China. Eligible patients (>18 years old) with newly diagnosed APL and achieved complete remission(CR) were enrolled since May 2019, with final follow-up in July 31,2021. Interventions: The consolidation therapy included realgar-Indigo naturalis formula (60 mg/kg daily in an oral divided dose) in a 4-week-on and4-week-off regimen for 4 cycles and ATRA (25 mg/m 2 daily in anoral divided dose) in a 2-week-on and 2-week-off regimen for 7 cycles. The primary endpoint was the 2-year DFS. Secondary endpoints included complete molecular remission (CMR) defined as the absence of detectable PML-RARA transcripts., event-free survival (EFS), OS, and safety. Main outcomes and measures: 38 eligible patients were enrolled including 18 males and 20 females and the median age was 41 years old (18-77 years). The median of WBC count is 25.39(10.2-113.9)×109/L[ >50×10 9/L n=10; (20-50)×10 9/L n=14,(10-20)×10 9/L n=14].All the patients achieved CMR during post-remission treatment phase (7 months). Until now, no molecular, hematologic recurrence,and central nervous system leukemia has happened with median follow-up of 13 months. What's more, this chemotherapy-free, completely oral regimen was well tolerated. C onclusions: These exciting results proved that RIF plus retinoic acid as postremission treatment of high-risk APL was effective, safe and convenient. The study is ongoing, and the effective of this regimen need to be evaluated by more patients and longer time. Figure 1. The overall survival(OS) and disease-free survival (DFS) of high-risk APL patients. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia

Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia

Long-Term Efficacy Of Low-Dose All-Trans Retinoic Acid Plus Minimal Chemotherapy Induction Followed By The Addition Of Intravenous Arsenic Trioxide Post-Remission Therapy In Newly Diagnosed Acute Promyelocytic Leukaemia

Arsenic Trioxide Replacing or Reducing Chemotherapy in Consolidation Therapy for Acute Promyelocytic Leukemia (APL2012 Trial)

High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.

Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy.

The Clinical Efficacy of All-Trans Retinoic Acid Plus Arsenic Trioxide in 177 Newly Diagnosed Acute Promyelocytic Leukemia Patients

Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia

Oral Realgar-Indigo Naturalis Formula Achieved Comparably High Rate Of Remission And Survival To Intravenous Arsenic Trioxide As A Front-Line Treatment In Newly Diagnosed Acute Promyelocytic Leukemia: A Multi-Center Randomized Trial Aplo7

Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.

All-Trans Retinoic Acid Plus Arsenic Trioxide Versus All-Trans Retinoic Acid Plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis

Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy

Outcomes and Prognostic Factors of First Relapsed Acute Promyelocytic Leukemia Patients Undergoing Salvage Therapy with Intravenous Arsenic Trioxide and Chemotherapy

The Simpler, The Better: Oral Arsenic For Acute Promyelocytic Leukemia

Highly Curative Treatment of High-Risk Acute Promyelocytic Leukemia: Induction and Consolidation with ATRA+ATO+anthracyclines and Maintenance with ATRA+RIF

Realgar Indigo Formula Plus ATRA As Postremission Treatment in an Rral and Chemo-Free Model for High-Risk Acute Promyelocytic Leukemia Patients: A Prospective, Multicenter, Phase II Study

An Effective and Chemotherapy-Free Strategy of All-Trans Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia in All Risk Groups (APL15 Trial)

The Simpler the Better: Oral Arsenic for Acute Promyelocytic Leukemia.

Combining Retinoic Acid and Oral Arsenic May Be Potentially the First-Line Therapy for Non-High-risk Acute Promyelocytic Leukemia.

Treatment Outcomes in Relapsed Acute Promyelocytic Leukemia Patients Initially Treated with All-Trans Retinoic Acid and Arsenic Compound-Based Combined Therapies

Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study